Abstract
Among the chemometric tools used in rational drug design, we find artificial neural network methods (ANNs), a statistical learning algorithm similar to the human brain, to be quite powerful. Some ANN applications use biological and molecular data of the training series that are inserted to ensure the machine learning, and to generate robust and predictive models. In drug discovery, researchers use this methodology, looking to find new chemotherapeutic agents for various diseases. The neglected diseases are a group of tropical parasitic diseases that primarily affect poor countries in Africa, Asia, and South America. Current drugs against these diseases cause side effects, are ineffective during the chronic stages of the disease, and are often not available to the needy population, have relative high toxicity, and face developing resistance. Faced with so many problems, new chemotherapeutic agents to treat these infections are much needed. The present review reports on neural network research, which studies new ligands against Chagas’ disease, sleeping sickness, malaria, tuberculosis, and leishmaniasis; a few of the neglected diseases.
Keywords: Artificial neural network, Chagas’ disease, chemometrics tools, drug discovery, leishmaniasis, malaria, sleeping sickness, tuberculosis.
Combinatorial Chemistry & High Throughput Screening
Title:Artificial Neural Network Methods Applied to Drug Discovery for Neglected Diseases
Volume: 18 Issue: 8
Author(s): Luciana Scotti, Hamilton Ishiki, Francisco J.B. Mendonça Júnior, Marcelo S. da Silva and Marcus T. Scotti
Affiliation:
Keywords: Artificial neural network, Chagas’ disease, chemometrics tools, drug discovery, leishmaniasis, malaria, sleeping sickness, tuberculosis.
Abstract: Among the chemometric tools used in rational drug design, we find artificial neural network methods (ANNs), a statistical learning algorithm similar to the human brain, to be quite powerful. Some ANN applications use biological and molecular data of the training series that are inserted to ensure the machine learning, and to generate robust and predictive models. In drug discovery, researchers use this methodology, looking to find new chemotherapeutic agents for various diseases. The neglected diseases are a group of tropical parasitic diseases that primarily affect poor countries in Africa, Asia, and South America. Current drugs against these diseases cause side effects, are ineffective during the chronic stages of the disease, and are often not available to the needy population, have relative high toxicity, and face developing resistance. Faced with so many problems, new chemotherapeutic agents to treat these infections are much needed. The present review reports on neural network research, which studies new ligands against Chagas’ disease, sleeping sickness, malaria, tuberculosis, and leishmaniasis; a few of the neglected diseases.
Export Options
About this article
Cite this article as:
Scotti Luciana, Ishiki Hamilton, Mendonça Júnior J.B. Francisco, da Silva S. Marcelo and Scotti T. Marcus, Artificial Neural Network Methods Applied to Drug Discovery for Neglected Diseases, Combinatorial Chemistry & High Throughput Screening 2015; 18 (8) . https://dx.doi.org/10.2174/1386207318666150803141219
DOI https://dx.doi.org/10.2174/1386207318666150803141219 |
Print ISSN 1386-2073 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5402 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Erythropoietin: A Neuroprotective Agent in Cerebral Hypoxia, Neurodegeneration, and Epilepsy
Current Pharmaceutical Design Carbon Nanotubes as an Advanced Drug and Gene Delivery Nanosystem
Current Nanoscience Positive Aspects, Negative Aspects and Challenges Associated with Stem Cell Therapy for COVID - 19: A Mini-review
Current Stem Cell Research & Therapy Effects of Diabetes on Murine Lipoproteins and Vascular Disease
Current Drug Targets The Role of the Gut Microbiota in Energy Metabolism and Metabolic Disease
Current Pharmaceutical Design Possible Involvement of TRP Channels in Cardiac Hypertrophy and Arrhythmia
Current Topics in Medicinal Chemistry Nitric Oxide-Mediated Endothelial Dysfunction - Is there Need to Treat?
Current Vascular Pharmacology Mitochondrial-Targeted Antioxidants and Oxidative Stress: A Proteomic Prospective Study
Current Pharmaceutical Design Neutrophil Function in Severe Sepsis
Endocrine, Metabolic & Immune Disorders - Drug Targets Nucleic Acids as Therapeutic Agents
Current Topics in Medicinal Chemistry Update on the Biologic Role of the Vitamin D Endocrine System
Current Vascular Pharmacology Polyphenols and Depression: from Chemistry to Medicine
Current Pharmaceutical Biotechnology Protein-C Reactive as Biomarker Predictor of Schizophrenia Phases of Illness? A Systematic Review
Current Neuropharmacology Anti-Inflammatory Effects of Alkaline Phosphatase in Coronary Artery Bypass Surgery with Cardiopulmonary Bypass
Recent Patents on Inflammation & Allergy Drug Discovery Total Carotenoids Content and Assessment of Carotene Profile by High- Performance Liquid Chromatography in Selected Vegetables of Bangladesh with Special Reference to Some Unconventional Varieties
Current Chromatography Relevance of the Vascular Effects of Insulin in the Rationale of its Therapeutical Use
Cardiovascular & Hematological Disorders-Drug Targets Risk Profiles in Type 2 Diabetes (Metabolic Syndrome): Integration of IL-10 Polymorphisms and Laboratory Parameters to Identify Vascular Damages Related Complications
Current Pharmaceutical Design Management of Obesity
Current Respiratory Medicine Reviews Protein-protein Interactions: Network Analysis and Applications in Drug Discovery
Current Pharmaceutical Design Clinical Efficacy of Remdesivir and Favipiravir in the Treatment of COVID-19 Patients: Scenario so far
Current Drug Research Reviews